Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematolog… (NCT07312058) | Clinical Trial Compass
RecruitingNot Applicable
Long-term Evaluation of Fertility Preservation Options in Women in Cancer Remission or Haematological Pathology
France102 participantsStarted 2025-12-17
Plain-language summary
Cancer treatments, despite their increasing effectiveness, carry a significant risk of gamete toxicity.
Women of reproductive age are commonly offered fertility preservation (FP) before starting their treatment.
However, few studies have analyzed the long-term reproductive outcomes of these interventions, nor how patients ultimately use or do not use the FP options once in remission.
This project aims to better understand the effectiveness, utilization, and psychological impacts of these strategies.
This work is part of an effort to understand and evaluate fertility preservation practices implemented for women of reproductive age undergoing cancer treatment at the Amiens-Picardie University Hospital (CHU).
Its objective is to document patient pathways, clinical decisions, techniques employed, and reproductive outcomes observed after remission, in order to identify potential areas for improvement in the support and follow-up of these patients, thereby enhancing the overall quality and coordination of care.
This work is conducted alongside the development of a fertility observatory at the Department of Medicine and Reproductive Biology, CHU Amiens-Picardie.
Who can participate
Age range
18 Years – 47 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Women
* Aged between 18 and 47 years
* Diagnosed with cancer or hematological disorders requiring potentially gonadotoxic treatment
* Having undergone a medical fertility preservation consultation
* Followed at Amiens Picardie University Hospital (CHU Amiens Picardie) in the department of Reproductive Medicine
* Currently in remission
* Having expressed non-opposition to participation in the study
Exclusion Criteria:
* Absence of remission
* Patients deprived of liberty by administrative or judicial decision, or placed under legal protection (guardianship or curators)
* Decline to participate in the study
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Occurrence of an identifiable reproductive outcome